PM
PMV Pharmaceuticals, Inc.
PMVP · NASDAQ
$1.50 +3.45% (+$0.05)
1M +14.50%
Market Cap $80.0M
P/E Ratio -
Div. Yield -
ROE 78.11%
Bulios Fair Price
$1.96
30.7% upside
Current Price
$1.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PMVP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 1.12x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 24.78%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 78.11%
ROA 91.66%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 7.70x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
48 /100
Moderate EPS volatility 26.94%
Profitable years 0
Beta 1.37x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PMVP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David H. Mack
Employees
54
Headquarters
Princeton
Upcoming events
11 NOV
Earnings
Upcoming earnings report